AND ESTABLISHING A LEADING SPECIALTY EQUIPMENT MANUFACTURER OCTOBER 30, 2025 E X E C U T E • I N N O V A T E • G R O W 1 Cautionary Statement About Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933, which involve risks and uncertainties. Any statements about Terex's and REV Group's, or the combined company's plans, objectives, expectations, strategies, beliefs ...

Core Viewpoint - The merger between Mallinckrodt plc and Endo, Inc. is set to close in early August 2025, following the Irish High Court's ruling and shareholder approvals, aiming to create a diversified global therapeutics leader [1][2][3] Company Overview - Mallinckrodt is a global business with multiple subsidiaries focused on developing, manufacturing, marketing, and distributing specialty pharmaceutical products, particularly in areas like autoimmune and rare diseases, neonatal respiratory care, and gastrointestinal products [5] - Endo is a diversified pharmaceutical company dedicated to transforming insights into life-enhancing therapies, with a commitment to delivering essential medicines [7] Merger Details - The merger involves a stock and cash transaction, with Mallinckrodt's headquarters in Dublin serving as the global headquarters for the combined entity [1][2] - The companies plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business, with a future separation of these businesses subject to board approval [3] Leadership - Siggi Olafsson, President and CEO of Mallinckrodt, will continue in the same role for the combined company, emphasizing the opportunity for value creation for shareholders, customers, and employees [3] Advisory Teams - Mallinckrodt's financial advisor is Lazard, with legal counsel from Wachtell, Lipton, Rosen & Katz, Hogan Lovells, and Arthur Cox. Endo's financial advisor is Goldman Sachs & Co. LLC, with legal counsel from Davis Polk & Wardwell LLP, Paul, Weiss, Rifkind, Wharton & Garrison LLP, and A&L Goodbody LLP [4]

Company Overview - The Shyft Group, Inc. is a leader in specialty vehicle manufacturing, assembly, and upfit for commercial, retail, and service markets in North America, reporting sales of $786 million in 2024 [5] - Aebi Schmidt Group is a global leader in intelligent solutions for infrastructure and agricultural applications, generating net sales of over 1 billion EUR in 2024 and employing around 3,000 people [6][7] Merger Details - Shareholders of Shyft approved the merger agreement with Aebi Schmidt, with approximately 99% of votes in favor, representing about 81% of total outstanding shares as of May 13, 2025 [2][3] - The merger is expected to close on or around July 1, 2025, with the combined company to be named "Aebi Schmidt Group" and trading on NASDAQ under the ticker symbol "AEBI" [1][3] - Each share of Shyft common stock will be exchanged for approximately 1.04 shares of the combined company's common stock upon completion of the merger [3] Strategic Implications - The merger aims to create a differentiated global leader in the specialty vehicles industry, enhancing scale, capabilities, and customer value [4] - The combined entity is expected to unlock meaningful value for customers and shareholders, positioning itself for continued growth [4]

Core Insights - BioSig Technologies, Inc. has entered into a Letter of Intent for a proposed merger with Streamex Exchange Corporation in an all-stock transaction [1] - The merger is viewed as a transformative opportunity that will unlock significant growth potential and enhance market reach for both companies [2] Proposed Terms of Merger - Post-merger, current stockholders of Streamex will own approximately 19.9% of BioSig's outstanding Common Stock, and after the conversion of Preferred Stock, they will own about 75% of the outstanding Common Stock [5] Management Changes - Henry McPhie, Co-Founder and CEO of Streamex, will become the new CEO of BioSig, while Morgan Lekstrom, Co-Founder and Chairman of Streamex, will serve as Chairman of the Board [6] - Anthony Amato, the current CEO and Chairman of BioSig, will remain on the Board [6] Strategic Advisor Additions - Frank Giustra will join as a Strategic Investor and Advisor on Commodities, with a notable background in founding major companies [6] - Mathew August and Mitchell Williams will serve as Strategic Advisors on US Capital Markets, bringing extensive experience in investment and venture capital [6]